News | July 23, 2025
Akums launches high-strength Paracetamol oral suspension 500mg/5ml
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Upgrades 2025 full-year CDMO sales and margin outlook
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Subscribe To Our Newsletter & Stay Updated
